BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/23/2024 4:13:00 AM | Browse: 392 | Download: 1147
Publication Name World Journal of Clinical Oncology
Manuscript ID 86850
Country China
Received
2023-08-30 02:12
Peer-Review Started
2023-08-30 02:14
First Decision by Editorial Office Director
2023-11-20 07:21
Return for Revision
2023-11-21 01:17
Revised
2023-12-02 15:22
Publication Fee Transferred
Editorial Processing by Scientific Editor
2023-12-18 03:51
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2023-12-25 06:49
Articles in Press
2023-12-25 06:49
Edit the Manuscript by Language Editor
2023-12-30 07:59
Typeset the Manuscript
2024-01-13 12:44
Publish the Manuscript Online
2024-01-23 04:13
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Yan Li, William Lee, Zhen-Gang Zhao, Yi Liu, Hao Cui and Hao-Yu Wang
ORCID
Author(s) ORCID Number
Yan Li http://orcid.org/0000-0003-2602-7423
William Lee http://orcid.org/0009-0008-2736-6025
Zhen-Gang Zhao http://orcid.org/0000-0001-7249-4474
Yi Liu http://orcid.org/0000-0001-8082-8868
Hao Cui http://orcid.org/0000-0002-5629-7814
Hao-Yu Wang http://orcid.org/0000-0001-6672-2733
Funding Agency and Grant Number
Funding Agency Grant Number
Tianjin Key Medical Discipline Construction Project TJYXZDXK-034A
Corresponding Author Yan Li, MD, Chief Physician, Department of Gastroenterology, Tianjin Third Central Hospital, 83 Jintang Road, Hedong District, Tianjin 300170, China. li13821177880@126.com
Key Words Hepatocellular carcinoma; Fatty acid binding protein; Novel target; Amplification; Correlated expression
Core Tip Several recent studies reported that fatty acid binding proteins (FABPs) contribute to reprogrammed lipid metabolism and cancer progression; however, how these FABPs are dysregulated in cancer, especially in hepatocellular carcinoma (HCC), has not been carefully addressed. We discovered that a FABP gene cluster including FABP5 are frequently amplified in cancer. FABP5 is significantly upregulated in HCC and its high expression correlates well with worse patient outcomes, enrichment of top enriched cancer hallmarks involved in cell cycle progression, and two oncogenes PLK1 and BIRC5 in HCC. FABP5 inhibition impaired the cell viability of FABP5high HCC cells. Our data supported that FABP5 is a novel therapeutic target for treating HCC.
Publish Date 2024-01-23 04:13
Citation Li Y, Lee W, Zhao ZG, Liu Y, Cui H, Wang HY. Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma. World J Clin Oncol 2024; 15(1): 130-144
URL https://www.wjgnet.com/2218-4333/full/v15/i1/130.htm
DOI https://dx.doi.org/10.5306/wjco.v15.i1.130
Full Article (PDF) WJCO-15-130-with-cover.pdf
Full Article (Word) WJCO-15-130.docx